Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Saltsjöbaden – page 51

771 clinical trials in Saltsjöbaden, Sweden across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Saltsjöbaden at a glance
771
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

771 trials in Saltsjöbaden

Open in trial search

Study Comparing Sonrotoclax and Zanubrutinib with Venetoclax and Obinutuzumab for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Study on the Effectiveness and Safety of GSK4527226 in Patients with Early Alzheimer's Disease

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Glaxosmithkline Research & Development Limited
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Betamethasone Sodium Phosphate
  • Sponsor:Uppsala Universitet

Study on Ravulizumab for Patients with Thrombotic Microangiopathy After Stem Cell Transplant

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

B-cell lymphoma

Not recruiting

Long-term Study of Zanubrutinib for Patients with B-cell Blood Cancer

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:BeOne Medicines AG

Study on the Effects of AMX0035 (Phenylbutyrate and Ursodoxicoltaurine) in Patients with Progressive Supranuclear Palsy

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Phenylbutyrate
  • Sponsor:Amylyx Pharmaceuticals Inc.

Hepatitis D

Not recruiting

Study on the Effects of RBD1016 and Tenofovir Alafenamide for Patients with Chronic Hepatitis D Infection

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:RBD1016
  • Sponsor:Ribocure Pharmaceuticals AB

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Study on the Safety and Immune Response of V116 Vaccine in Children and Adolescents at Higher Risk for Pneumococcal Disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:ABC-15BO-116
  • Sponsor:Merck Sharp & Dohme LLC

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Study on the Safety and Effectiveness of Adding Hydroxycarbamide to Standard Treatment with Cytarabine and Daunorubicin for Adults with Newly Diagnosed Acute Myeloid Leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Karolinska University Hospital

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Saltsjöbaden

What the registry says about research in the country

01 Diseases [C] - Virus Diseases [C02]

In Saltsjöbaden, clinical research in this area focuses on RSV infection and the immune response to prevention-focused interventions. These studies are looking at how well a new approach can support protection against respiratory viral illness in older adults.

  • RSV infection
  • Respiratory tract diseases
  • Evaluating immune protection against viral infection

The work is centered on understanding whether the intervention can strengthen the body’s defense against RSV and help reduce the impact of this common respiratory virus.

02 Diseases [C] - Respiratory Tract Diseases [C08]

This research field covers trials aimed at preventing or reducing illness related to respiratory tract diseases, with a strong focus on RSV infection. The main goal is to assess how effective a vaccine-based strategy may be in older adults.

  • Respiratory tract disease prevention
  • RSV antibody response
  • Testing a new preventive therapy

These studies help clarify whether the intervention can improve protection in populations more vulnerable to severe respiratory infections.

03 Diseases [C] - Bacterial Infections and Mycoses [C01]

Clinical trials in this therapeutic area are examining treatment options for Diabetic Foot Ulcer, a wound complication where infection control and healing are major concerns. The research is focused on finding better local antimicrobial care to support complete wound closure.

  • Diabetic Foot Ulcer
  • Bacterial infection management
  • Improving wound healing outcomes

In Sweden, this line of research is comparing approaches that may help clinicians choose more effective treatments for difficult-to-heal ulcers.

04 Diabetic Foot Ulcer

The trial activity around Diabetic Foot Ulcer is aimed at evaluating how well local antimicrobial agents help wounds heal. It is a practical, patient-centered area of research focused on treatment effectiveness and recovery.

  • Local antimicrobial treatment
  • Time to healing
  • Wound care and infection control

These studies are intended to improve everyday care for people living with chronic foot ulcers linked to diabetes.

05 RSV infection

Research on RSV infection is centered on prevention and immune response in older adults, especially those at higher risk of severe disease. The trials are assessing whether a new protective strategy can generate helpful neutralizing antibodies.

  • Older adult respiratory health
  • Immune response to RSV
  • Preventive vaccine research

This work supports better understanding of how to reduce the burden of RSV in aging populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.